Home LiteratureArticle Details
PMID: 22277903 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review

Differential macrophage programming in the tumor microenvironment.

Trends in immunology ·Vol. 33 ·No. 3 ·2012-03-00 ·Pages 119-26

Ruffell B, Affara NI, Coussens LM

Abstract

Of the multiple unique stromal cell types common to solid tumors, tumor-associated macrophages (TAMs) are significant for fostering tumor progression. The protumor properties of TAMs derive from regulation of angiogenic programming, production of soluble mediators that support proliferation, survival and invasion of malignant cells, and direct and indirect suppression of cytotoxic T cell activity. These varied activities are dependent on the polarization state of TAMs that is regulated in part by local concentrations of cytokines and chemokines, as well as varied interactions of TAMs with normal and degraded components of the extracellular matrix. Targeting molecular pathways regulating TAM polarization holds great promise for anticancer therapy.

MeSH Terms
Animals Humans Macrophages/immunology Neoplasm Invasiveness Neoplasm Metastasis Neoplasms/blood supply,immunology,pathology Neovascularization, Pathologic Tumor Microenvironment
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Ruffell Brian
Department of Pathology, University of California, San Francisco, 513 Parnassus Ave, HSW450C, San Francisco, CA 94143, USA.
Affara Nesrine I
Coussens Lisa M
References (132)
132 references, click to expand
  1. Nutrient sensing and inflammation in metabolic diseases.
    Nat Rev Immunol. 2008 Dec;8(12):923-34 PMID: 19029988
  2. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
    Nat Med. 2007 Sep;13(9):1050-9 PMID: 17704786
  3. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
    Int J Cancer. 1999 Oct 22;84(5):538-43 PMID: 10502735
  4. Matrix crosslinking forces tumor progression by enhancing integrin signaling.
    Cell. 2009 Nov 25;139(5):891-906 PMID: 19931152
  5. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis.
    Cancer Cell. 2008 Oct 7;14(4):299-311 PMID: 18835032
  6. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer.
    J Surg Oncol. 2010 Sep 1;102(3):242-8 PMID: 20740582
  7. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.
    Cancer Cell. 2005 Sep;8(3):211-26 PMID: 16169466
  8. Imaging and quantifying the dynamics of tumor-associated proteolysis.
    Clin Exp Metastasis. 2009;26(4):299-309 PMID: 19082919
  9. Dendritic cell and macrophage heterogeneity in vivo.
    Immunity. 2011 Sep 23;35(3):323-35 PMID: 21943488
  10. Lymphocytes in cancer development: polarization towards pro-tumor immunity.
    Cytokine Growth Factor Rev. 2010 Feb;21(1):3-10 PMID: 20005150
  11. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer.
    Clin Exp Metastasis. 2007;24(2):121-30 PMID: 17390111
  12. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.
    Cancer Cell. 2011 Apr 12;19(4):512-26 PMID: 21481792
  13. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.
    Lancet. 2011 Jan 1;377(9759):31-41 PMID: 21144578
  14. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
    Science. 2011 Mar 25;331(6024):1612-6 PMID: 21436454
  15. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression.
    Int J Cancer. 2009 Sep 15;125(6):1276-84 PMID: 19479998
  16. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response.
    Neoplasia. 2008 Apr;10(4):329-40 PMID: 18392134
  17. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors.
    Pathol Int. 2009 May;59(5):300-5 PMID: 19432671
  18. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment.
    Neoplasia. 2009 Nov;11(11):1235-42 PMID: 19881959
  19. Macrophage diversity enhances tumor progression and metastasis.
    Cell. 2010 Apr 2;141(1):39-51 PMID: 20371344
  20. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
    Int J Cancer. 2005 Feb 10;113(4):525-32 PMID: 15472905
  21. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis.
    Nature. 2008 Dec 11;456(7223):814-8 PMID: 18997773
  22. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.
    Cancer Cell. 2009 Aug 4;16(2):91-102 PMID: 19647220
  23. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors.
    Am J Pathol. 2009 Mar;174(3):1048-64 PMID: 19218341
  24. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.
    Cell. 2005 May 6;121(3):335-48 PMID: 15882617
  25. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development.
    Nature. 2011 Nov 09;479(7374):547-51 PMID: 22080947
  26. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.
    Cancer Cell. 2010 Feb 17;17(2):135-47 PMID: 20138012
  27. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation.
    J Clin Invest. 2010 Aug;120(8):2699-714 PMID: 20644254
  28. Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters.
    J Exp Clin Cancer Res. 2006 Sep;25(3):365-72 PMID: 17167977
  29. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.
    Carcinogenesis. 2009 Mar;30(3):377-86 PMID: 19136477
  30. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer.
    Cancer Res. 2006 May 15;66(10):5242-50 PMID: 16707449
  31. Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma.
    Int J Cancer. 2010 Mar 15;126(6):1339-52 PMID: 19711348
  32. Matrix metalloproteinases: regulators of the tumor microenvironment.
    Cell. 2010 Apr 2;141(1):52-67 PMID: 20371345
  33. Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland.
    Dev Dyn. 2006 Dec;235(12):3222-9 PMID: 17029292
  34. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.
    Cancer Res. 2007 Sep 15;67(18):8900-5 PMID: 17875732
  35. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment.
    Proc Natl Acad Sci U S A. 2010 May 4;107(18):8363-8 PMID: 20404138
  36. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.
    Cancer Cell. 2008 Mar;13(3):206-20 PMID: 18328425
  37. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival.
    Int J Oncol. 2000 Sep;17(3):445-51 PMID: 10938382
  38. EGFR antagonists in cancer treatment.
    N Engl J Med. 2008 Mar 13;358(11):1160-74 PMID: 18337605
  39. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  40. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.
    J Exp Med. 2011 Sep 26;208(10):1949-62 PMID: 21930770
  41. Cysteine cathepsins: multifunctional enzymes in cancer.
    Nat Rev Cancer. 2006 Oct;6(10):764-75 PMID: 16990854
  42. Origin and physiological roles of inflammation.
    Nature. 2008 Jul 24;454(7203):428-35 PMID: 18650913
  43. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis.
    J Exp Med. 2009 May 11;206(5):1089-102 PMID: 19398755
  44. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis.
    Nature. 2009 Jan 1;457(7225):102-6 PMID: 19122641
  45. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers.
    Cancer Res. 2000 May 15;60(10):2632-5 PMID: 10825134
  46. Alternative activation of macrophages.
    Nat Rev Immunol. 2003 Jan;3(1):23-35 PMID: 12511873
  47. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.
    Cancer Res. 2010 Jul 15;70(14):5728-39 PMID: 20570887
  48. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.
    Cell. 2006 Jan 27;124(2):263-6 PMID: 16439202
  49. Partial regression in primary carcinoma of the lung: does it occur?
    Histopathology. 1998 Jul;33(1):55-63 PMID: 9726050
  50. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors.
    Cancer Res. 2007 Mar 15;67(6):2649-56 PMID: 17363585
  51. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.
    J Immunol. 2011 Aug 1;187(3):1157-65 PMID: 21709158
  52. FcRgamma activation regulates inflammation-associated squamous carcinogenesis.
    Cancer Cell. 2010 Feb 17;17(2):121-34 PMID: 20138013
  53. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination.
    Clin Cancer Res. 2009 Apr 1;15(7):2433-41 PMID: 19318480
  54. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression.
    Cancer Res. 2010 Oct 1;70(19):7465-75 PMID: 20841473
  55. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density.
    Oncol Rep. 2005 Aug;14(2):425-31 PMID: 16012726
  56. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
    Cancer Discov. 2011 Jun;1(1):54-67 PMID: 22039576
  57. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.
    Lancet. 2010 Nov 20;376(9754):1741-50 PMID: 20970847
  58. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.
    J Pathol. 2002 Mar;196(3):254-65 PMID: 11857487
  59. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
    Cancer Cell. 2009 Mar 3;15(3):220-31 PMID: 19249680
  60. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.
    Nat Rev Immunol. 2005 Apr;5(4):331-42 PMID: 15803152
  61. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis.
    J Immunol. 2011 Dec 1;187(11):5703-11 PMID: 22048774
  62. Prognostic value of tumor-associated macrophage count in human bladder cancer.
    Int J Urol. 2000 Jul;7(7):263-9 PMID: 10910229
  63. Resolution of inflammation: the beginning programs the end.
    Nat Immunol. 2005 Dec;6(12):1191-7 PMID: 16369558
  64. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma.
    Cancer Res. 1996 Oct 15;56(20):4625-9 PMID: 8840975
  65. Fibrocytes: emerging effector cells in chronic inflammation.
    Nat Rev Immunol. 2011 Jun;11(6):427-35 PMID: 21597472
  66. The parallel lives of angiogenesis and immunosuppression: cancer and other tales.
    Nat Rev Immunol. 2011 Sep 23;11(10):702-11 PMID: 21941296
  67. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.
    J Clin Invest. 2004 Sep;114(5):623-33 PMID: 15343380
  68. Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A.
    Melanoma Res. 2005 Oct;15(5):417-25 PMID: 16179869
  69. Microenvironmental regulation of metastasis.
    Nat Rev Cancer. 2009 Apr;9(4):239-52 PMID: 19279573
  70. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis.
    Nature. 2007 Oct 4;449(7162):557-63 PMID: 17914389
  71. Macrophage death and defective inflammation resolution in atherosclerosis.
    Nat Rev Immunol. 2010 Jan;10(1):36-46 PMID: 19960040
  72. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion.
    Genes Dev. 2010 Feb 1;24(3):241-55 PMID: 20080943
  73. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.
    J Exp Med. 2009 Jun 8;206(6):1327-37 PMID: 19451266
  74. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression.
    Int J Cancer. 1993 Aug 19;55(1):96-101 PMID: 8344757
  75. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  76. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation.
    Kidney Int. 2001 Aug;60(2):614-25 PMID: 11473644
  77. Chemotaxis in cancer.
    Nat Rev Cancer. 2011 Jul 22;11(8):573-87 PMID: 21779009
  78. Trophic macrophages in development and disease.
    Nat Rev Immunol. 2009 Apr;9(4):259-70 PMID: 19282852
  79. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.
    Cancer Cell. 2011 Jan 18;19(1):31-44 PMID: 21215706
  80. Cooperative phagocytes: resident microglia and bone marrow immigrants remove dead photoreceptors in retinal lesions.
    Am J Pathol. 2009 Jun;174(6):2310-23 PMID: 19435787
  81. Tumor-associated macrophages: the double-edged sword in cancer progression.
    J Clin Oncol. 2005 Feb 10;23(5):953-64 PMID: 15598976
  82. Interleukin-10 and the interleukin-10 receptor.
    Annu Rev Immunol. 2001;19:683-765 PMID: 11244051
  83. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps.
    Carcinogenesis. 2011 Sep;32(9):1333-9 PMID: 21730361
  84. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10.
    J Immunol. 1995 Apr 1;154(7):3383-90 PMID: 7897221
  85. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).
    Blood. 2006 Mar 1;107(5):2112-22 PMID: 16269622
  86. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.
    Nature. 2011 Jun 08;475(7355):222-5 PMID: 21654748
  87. Hypoxia-inducible factors as essential regulators of inflammation.
    Curr Top Microbiol Immunol. 2010;345:105-20 PMID: 20517715
  88. Leukocytes in mammary development and cancer.
    Cold Spring Harb Perspect Biol. 2011 Mar 01;3(3): PMID: 21123394
  89. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.
    Cancer Res. 2005 Apr 15;65(8):3437-46 PMID: 15833879
  90. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
    J Exp Med. 2003 Dec 1;198(11):1741-52 PMID: 14657224
  91. Foamy macrophages and the progression of the human tuberculosis granuloma.
    Nat Immunol. 2009 Sep;10(9):943-8 PMID: 19692995
  92. Tumor angiogenesis.
    N Engl J Med. 2008 May 8;358(19):2039-49 PMID: 18463380
  93. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression.
    Cancer Cell. 2004 Sep;6(3):297-305 PMID: 15380520
  94. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
    J Clin Oncol. 2005 Nov 1;23(31):8136-9 PMID: 16258121
  95. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response.
    J Immunol. 1995 Aug 15;155(4):2240-7 PMID: 7636270
  96. Dynamics of the immune reaction to pancreatic cancer from inception to invasion.
    Cancer Res. 2007 Oct 1;67(19):9518-27 PMID: 17909062
  97. The impact of the extracellular matrix on inflammation.
    Nat Rev Immunol. 2010 Oct;10(10):712-23 PMID: 20865019
  98. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis.
    Cancer Res. 2004 May 1;64(9):2941-55 PMID: 15126324
  99. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
    J Clin Oncol. 2006 Jan 1;24(1):16-24 PMID: 16330672
  100. Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production.
    J Leukoc Biol. 2004 Jul;76(1):227-36 PMID: 15075356
  101. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.
    Mol Cell Biol. 1992 Mar;12(3):954-61 PMID: 1312220
  102. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis.
    J Leukoc Biol. 2006 Dec;80(6):1183-96 PMID: 16997855
  103. Shaping gene expression in activated and resting primary macrophages by IL-10.
    J Immunol. 2002 Sep 1;169(5):2253-63 PMID: 12193690
  104. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice.
    Cancer Res. 2004 Aug 1;64(15):5378-84 PMID: 15289345
  105. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.
    J Clin Invest. 2011 Oct;121(10):4015-29 PMID: 21911941
  106. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages.
    Mol Oncol. 2007 Dec;1(3):288-302 PMID: 18509509
  107. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages.
    J Immunol. 2000 Jan 15;164(2):762-7 PMID: 10623821
  108. TLR7 and TLR8 as targets in cancer therapy.
    Oncogene. 2008 Jan 7;27(2):190-9 PMID: 18176600
  109. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors.
    Cancer Res. 2004 Oct 1;64(19):7022-9 PMID: 15466195
  110. Proteolytic networks in cancer.
    Trends Cell Biol. 2011 Apr;21(4):228-37 PMID: 21232958
  111. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas.
    Clin Cancer Res. 1999 May;5(5):1107-13 PMID: 10353745
  112. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
    Nat Immunol. 2010 Oct;11(10):889-96 PMID: 20856220
  113. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation.
    J Exp Med. 2011 Mar 14;208(3):479-90 PMID: 21339324
  114. The role of myeloid cells in the promotion of tumour angiogenesis.
    Nat Rev Cancer. 2008 Aug;8(8):618-31 PMID: 18633355
  115. NF-kappaB functions as a tumour promoter in inflammation-associated cancer.
    Nature. 2004 Sep 23;431(7007):461-6 PMID: 15329734
  116. The macrophage colony-stimulating factor 1 response signature in breast carcinoma.
    Clin Cancer Res. 2009 Feb 1;15(3):778-87 PMID: 19188147
  117. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships.
    Blood. 2009 Jul 23;114(4):901-14 PMID: 19383967
  118. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas.
    J Pathol. 2000 Oct;192(2):150-8 PMID: 11004690
  119. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma.
    J Immunol. 1992 Feb 15;148(4):1280-5 PMID: 1737940
  120. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
    Cell. 2007 Nov 2;131(3):463-75 PMID: 17981115
  121. Mesenchymal stem cells in health and disease.
    Nat Rev Immunol. 2008 Sep;8(9):726-36 PMID: 19172693
  122. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft.
    J Invest Dermatol. 2007 Aug;127(8):2031-41 PMID: 17460736
  123. Differential use of chondroitin sulfate to regulate hyaluronan binding by receptor CD44 in Inflammatory and Interleukin 4-activated Macrophages.
    J Biol Chem. 2011 Jun 3;286(22):19179-90 PMID: 21471214
  124. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages.
    Clin Dev Immunol. 2010;2010:547179 PMID: 21331365
  125. "Re-educating" tumor-associated macrophages by targeting NF-kappaB.
    J Exp Med. 2008 Jun 9;205(6):1261-8 PMID: 18490490
  126. MCSF expression is induced in healing myocardial infarcts and may regulate monocyte and endothelial cell phenotype.
    Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H483-92 PMID: 12689859
  127. Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development.
    Oncogene. 2012 Mar 15;31(11):1459-67 PMID: 21822305
  128. Inflammatory links between obesity and metabolic disease.
    J Clin Invest. 2011 Jun;121(6):2111-7 PMID: 21633179
  129. Immune enhancement of skin carcinogenesis by CD4+ T cells.
    J Exp Med. 2003 Apr 21;197(8):1017-28 PMID: 12695493
  130. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer.
    J Pathol. 2000 Mar;190(4):430-6 PMID: 10699991
  131. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
    J Exp Med. 2006 Apr 17;203(4):871-81 PMID: 16606666
  132. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer.
    Br J Cancer. 2008 Mar 25;98(6):1118-24 PMID: 18283317
Article Info
Journal
Trends in immunology
Abbr.
Trends Immunol
ISSN
1471-4981
DOI
10.1016/j.it.2011.12.001
Published
2012-03-00
Epub
2012-00-23
Pages
119-26
Language
English
Region
England
NLM ID
100966032
PMCID
PMC3294003
Subset
IM
Grants
NCI NIH HHS · R01CA130980 · United States
NCI NIH HHS · R01 CA130980-04 · United States
NCI NIH HHS · R01 CA155331 · United States
NCI NIH HHS · R01 CA155331-01 · United States
NCI NIH HHS · R01 CA140943-03 · United States
NCI NIH HHS · R01CA140943 · United States
NCI NIH HHS · R01CA132566 · United States
NCI NIH HHS · R01 CA140943 · United States
NCI NIH HHS · R01 CA130980 · United States
NCI NIH HHS · R01 CA130980-02 · United States
NCI NIH HHS · R01 CA140943-02 · United States
NCI NIH HHS · R01 CA130980-01A1 · United States
NCI NIH HHS · R01 CA132566-05 · United States
NCI NIH HHS · R01 CA130980-03 · United States
NCI NIH HHS · R01 CA140943-01 · United States
NCI NIH HHS · R01 CA132566 · United States
NCI NIH HHS · R01 CA130980-05 · United States
NCI NIH HHS · R01 CA155331-02 · United States
NCI NIH HHS · R01 CA140943-04 · United States
External Links
PubMed source DOI: 10.1016/j.it.2011.12.001 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2